PressAugust 26, 2022 Cybin: Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial – Form 6-K
PressAugust 25, 2022 BetterLife Lead Drug (BETR-001) Promotes Structural Neural Plasticity with Possible Nootropic Effects Similar to That of LSD Without Hallucinogenic Side Effects
PressAugust 25, 2022 MindMed Announces First Patient Dosed in Phase 2b Trial of MM-120 in Generalized Anxiety Disorder
PressAugust 25, 2022 Optimi Health Announces Canadian Retail and E-Commerce Distribution Agreements for Functional Mushroom Supplements and Appoints Chief Financial Officer to its Board of Directors
PressAugust 24, 2022 Freedom Biosciences Emerges from Stealth with $10.5 Million Seed Financing to Develop Next-Generation Ketamine and Psychedelic-based Mental Health Treatments
PressAugust 24, 2022 Innovation1 Biotech Announces Filing of Patent Application for Novel Combination Therapy Targeting Addiction
PressAugust 24, 2022 NRx Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Results Focusing on Reactivation & Advancement of its Psychiatry Franchise
PressAugust 24, 2022 GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
PressAugust 24, 2022 Clearmind Medicine Announces Additional Positive Pre-Clinical Results for its Cocaine Addiction Treatment
PressAugust 24, 2022 Algernon Pharmaceuticals’ Largest Shareholder AlphaNorth Asset Management Increases Ownership Position
PressAugust 23, 2022 Core One Labs’: Akome Achieves Significant Research Milestone with Positive Neurogenesis Stimulation Studies Results
PressAugust 23, 2022 Field Trip Health & Wellness Ltd. Schedules Fiscal First Quarter 2023 Conference Call for Tuesday, August 30, 2022, at 8:30 A.M. ET
PressAugust 23, 2022 Another Public Company First: Silo Wellness Opens Jamaican Ecotourism Psilocybin Microdosing Resort for the Psychedelic Curious; Shareholder Discounts for Psychedelic Vacations Available
PressAugust 23, 2022 Mydecine Innovations Group Announces Private Placement; Interim Changes to Management and Board of Directors
PressAugust 23, 2022 Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada
PressAugust 22, 2022 Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans
PressAugust 22, 2022 Core One Labs’ Akome Achieves Another Milestone in Development of its Psychedelic Drug Formulas and Announces Positive Results from Neuro-Pharmacokinetics Studies
